Ironwood Pharmaceuticals Inc (IRWD) shareholders
Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Steven Boyd Joint filing with Armistice Capital, LLC (9.22%) | 15,028,000 | 9.22% | 13G (passive) amendment | Mar 31, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (8.43%) | 13,932,000 | 8.43% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 13,373,568 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Pacer Advisors, Inc. Joint filing with Joe M. Thomson (7.32%), Pacer US Small Cap Cash Cows ETF (7.31%) | 11,730,771 | 7.32% | 13G (passive) | Dec 31, 2024 |
| Alexander J. Denner Joint filing with Sarissa Capital Management LP (5.60%) | 9,444,944 | 5.80% | 13D (active) amendment | Mar 17, 2026 |
| Renaissance Technologies LLC Joint filing with Renaissance Technologies Holdings Corporation (5.37%) | 8,597,198 | 5.37% | 13G (passive) | May 15, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IRWD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 17,788,557 | 10.77% | $74.89M | +4,425,627 | 0.00% |
| Armistice Capital, LLC | 13,932,000 | 8.43% | $58.65M | −1,096,000 | 0.72% |
| Sarissa Capital Management LP | 9,188,635 | 5.56% | $38.68M | – | 21.75% |
| State Street Corp | 8,809,601 | 5.33% | $37.09M | +1,352,657 | 0.00% |
| Bank Of America Corp /De/ | 8,683,803 | 5.26% | $36.56M | +896 | 0.00% |
| Renaissance Technologies LLC | 7,993,226 | 4.84% | $33.65M | −67,847 | 0.05% |
| Vanguard Capital Management LLC | 6,608,508 | 4.00% | $27.82M | +511,054 | 0.00% |
| Aqr Capital Management LLC | 6,465,921 | 3.91% | $27.22M | −1,069,159 | 0.01% |
| Acadian Asset Management LLC | 5,853,331 | 3.54% | $24.62M | −723,941 | 0.03% |
| Vanguard Portfolio Management LLC | 5,513,355 | 3.34% | $23.21M | −1,168,682 | 0.00% |
| Geode Capital Management, LLC | 4,831,657 | 2.92% | $20.35M | +288,135 | 0.00% |
| Two Sigma Investments, LP | 4,556,089 | 2.76% | $19.18M | −1,292,187 | 0.01% |
| Marshall Wace, Llp | 4,290,093 | 2.60% | $18.06M | −234,971 | 0.01% |
| Jacobs Levy Equity Management, Inc | 4,065,964 | 2.46% | $17.12M | +433,487 | 0.06% |
| Goldman Sachs Group Inc | 3,313,808 | 2.01% | $13.95M | +623,174 | 0.00% |
| Charles Schwab Investment Management Inc | 3,302,242 | 2.00% | $13.90M | −1,435,615 | 0.00% |
| Federated Hermes, Inc. | 3,231,238 | 1.96% | $13.60M | −117,568 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 3,017,089 | 1.83% | $12.70M | −380,153 | 0.01% |
| Dimensional Fund Advisors LP | 2,522,891 | 1.53% | $10.62M | +440,836 | 0.00% |
| Mackenzie Financial Corp | 2,367,493 | 1.43% | $9.97M | +1,807,459 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 212 | 161M | 97.2% | 24 / 73 | 84 / 36 | 17M | 18M |
| Q1 2026 | 227 | 162M | 97.7% | 57 / 85 | 57 / 25 | 44M | 22M |
| Q4 2025 | 199 | 155M | 93.6% | 56 / 63 | 48 / 18 | 19M | 13M |
| Q3 2025 | 166 | 149M | 90.0% | 30 / 53 | 47 / 18 | 14M | 12M |
| Q2 2025 | 155 | 146M | 88.5% | 19 / 59 | 52 / 64 | 29M | 38M |
| Q1 2025 | 200 | 156M | 94.1% | 30 / 74 | 63 / 51 | 37M | 45M |
| Q4 2024 | 223 | 164M | 99.4% | 41 / 78 | 77 / 37 | 15M | 14M |
| Q3 2024 | 221 | 164M | 99.1% | 39 / 69 | 77 / 44 | 37M | 23M |
| Q2 2024 | 227 | 173M | 100.0% | 21 / 93 | 80 / 51 | 18M | 23M |
| Q1 2024 | 261 | 179M | 100.0% | 54 / 85 | 84 / 43 | 43M | 33M |
| Q4 2023 | 251 | 169M | 100.0% | 32 / 87 | 94 / 26 | 22M | 13M |
| Q3 2023 | 248 | 160M | 96.6% | 38 / 78 | 101 / 40 | 18M | 25M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
203 funds held IRWD in Q2 2026, 61% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IRWD | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,499,839 | 3.33% | $23.15M | 0.22% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,781,484 | 2.89% | $20.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,262,458 | 2.58% | $17.94M | 0.02% | Jun 30, 2026 |
| Schwab Fundamental U.S. Small Company ETF | 2,465,723 | 1.49% | $8.80M | 0.10% | May 31, 2026 |
| Vanguard Strategic Equity Fund | 1,833,231 | 1.11% | $7.72M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,790,034 | 1.08% | $7.57M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,677,797 | 1.02% | $7.06M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,413,903 | 0.86% | $5.95M | 0.04% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,403,741 | 0.85% | $5.94M | 0.03% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 1,286,341 | 0.78% | $5.44M | 0.24% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,116,521 | 0.68% | $4.70M | 0.05% | Jun 30, 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 1,079,411 | 0.65% | $4.57M | 0.12% | Jul 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 904,987 | 0.55% | $3.81M | 0.03% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 833,504 | 0.50% | $2.98M | 0.06% | May 29, 2026 |
| Vanguard Russell 2000 Index Fund | 823,033 | 0.50% | $2.94M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas A. MCCOURT | Chief Executive Officer, Director | 1,898,838 | 1.15% | Mar 12, 2026 |
| Jeffrey Silber | SVP, CMO, Head-Res&Drug | 137,036 | 0.08% | Jul 22, 2026 |
| Ronald Silver | PFO & PAO | 755,250 | 0.46% | Jul 9, 2026 |
| Tammi L. Gaskins | Chief Commercial Officer | 350,350 | 0.21% | Mar 12, 2026 |
| Michael Shetzline | SVP, CMO, Head-Res&Drug | 1,179,462 | 0.71% | Mar 12, 2026 |
| Minardo John | Chief Legal Officer | 500,498 | 0.30% | Mar 12, 2026 |
| Gregory S. Martini | Chief Financial Officer | 297,213 | 0.18% | Mar 12, 2026 |
| Sravan Kumar Emany | SVP, COO and CFO | 309,572 | 0.19% | Nov 20, 2024 |
| Andrew Davis | SVP, Chief Business Officer | 284,685 | 0.17% | Nov 20, 2024 |
| Alexander J. Denner | Director | 18,710,619 | 11.32% | Sep 17, 2026 |
| Jay Shepard | Director | 235,036 | 0.14% | Jun 17, 2026 |
| Jon R. Duane | Director | 253,820 | 0.15% | Jun 17, 2026 |
| Julie McHugh | Director | 272,320 | 0.16% | Jun 17, 2026 |
| Mark G. Currie | Director | 676,900 | 0.41% | Jun 17, 2026 |
| Catherine Moukheibir | Director | 181,425 | 0.11% | Jun 17, 2026 |
| Marla L. Kessler | Director | 229,364 | 0.14% | Jun 17, 2026 |
| Andrew Dreyfus | Director | 228,313 | 0.14% | Jun 12, 2025 |
| Capital Management LP Sarissa | 10% owner | 16,625,962 | 10.06% | Dec 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alexander J. Denner Director | Sep 15, 2026 | Award | +3,694 | – | – | 327,549 |
| Jeffrey Silber SVP, CMO, Head-Res&Drug | Jul 20, 2026 | Award | +137,036 | – | – | 137,036 |
| Ronald Silver PFO & PAO | Jul 7, 2026 | Sale(10b5-1 plan) | −127,890 | $4.52 | $578.06K | 313,680 |
| Alexander J. Denner Director | Jun 16, 2026 | Award | +63,481 | – | – | 323,855 |
| Julie McHugh Director | Jun 16, 2026 | Award | +63,481 | – | – | 272,320 |
| Julie McHugh Director | Jun 16, 2026 | Sale(10b5-1 plan) | −21,571 | $3.73 | $80.46K | 250,749 |
| Mark G. Currie Director | Jun 16, 2026 | Award | +63,481 | – | – | 676,900 |
| Marla L. Kessler Director | Jun 16, 2026 | Award | +63,481 | – | – | 229,364 |
| Catherine Moukheibir Director | Jun 16, 2026 | Award | +63,481 | – | – | 181,425 |
| Jay Shepard Director | Jun 16, 2026 | Award | +63,481 | – | – | 235,036 |
| Jon R. Duane Director | Jun 16, 2026 | Award | +63,481 | – | – | 253,820 |
| Alexander J. Denner Director | Jun 15, 2026 | Award | +4,065 | – | – | 260,374 |
| Ronald Silver PFO & PAO | May 19, 2026 | Award | +25,000 | – | – | 441,570 |
| Alexander J. Denner Director | Mar 17, 2026 | Sale | −6,725,000 | $3.05 | $20.51M | 9,194,435 |
| Alexander J. Denner Director | Mar 17, 2026 | Sale | −5,800 | $3.31 | $19.20K | 9,188,635 |
| Alexander J. Denner Director | Mar 13, 2026 | Award | +4,451 | – | – | 256,309 |
| Minardo John Chief Legal Officer | Mar 10, 2026 | Award | +136,612 | – | – | 500,498 |
| Ronald Silver Principal Accounting Officer | Mar 10, 2026 | Award | +163,934 | – | – | 416,570 |
| Thomas A. MCCOURT Chief Executive Officer, Director | Mar 10, 2026 | Award | +409,836 | – | – | 1,898,838 |
| Tammi L. Gaskins Chief Commercial Officer | Mar 10, 2026 | Award | +136,612 | – | – | 350,350 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Mar 10, 2026 | Award | +136,612 | – | – | 658,037 |
| Gregory S. Martini Chief Financial Officer | Mar 10, 2026 | Award | +136,612 | – | – | 297,213 |
| Gregory S. Martini Chief Financial Officer | Feb 24, 2026 | Sale | −11,457 | $3.66 | $41.93K | 160,601 |
| Thomas A. MCCOURT Chief Executive Officer, Director | Feb 24, 2026 | Sale | −103,526 | $3.66 | $378.91K | 1,489,002 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Feb 24, 2026 | Sale | +17,012 | $3.66 | $62.26K | 521,425 |
| Ronald Silver Principal Accounting Officer | Feb 24, 2026 | Sale | −12,621 | $3.66 | $46.19K | 252,636 |
| Minardo John Chief Legal Officer | Feb 24, 2026 | Sale | −19,053 | $3.66 | $69.73K | 363,886 |
| Tammi L. Gaskins Chief Commercial Officer | Feb 24, 2026 | Sale | −11,239 | $3.66 | $41.13K | 213,738 |
| Gregory S. Martini Chief Financial Officer | Feb 23, 2026 | Sale | −10,487 | $3.81 | $39.96K | 172,058 |
| Thomas A. MCCOURT Chief Executive Officer, Director | Feb 23, 2026 | Sale | −94,757 | $3.81 | $361.02K | 1,592,528 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Feb 23, 2026 | Sale | −15,570 | $3.81 | $59.32K | 538,437 |
| Ronald Silver Principal Accounting Officer | Feb 23, 2026 | Sale | −11,552 | $3.81 | $44.01K | 265,257 |
| Minardo John Chief Legal Officer | Feb 23, 2026 | Sale | −17,439 | $3.81 | $66.44K | 382,939 |
| Tammi L. Gaskins Chief Commercial Officer | Feb 23, 2026 | Sale | −10,287 | $3.81 | $39.19K | 224,977 |
| Ronald Silver Principal Accounting Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −35,416 | $4.60 | $162.91K | 276,809 |
| Alexander J. Denner Director, 10% owner | Dec 15, 2025 | Award | +4,178 | – | – | 251,858 |
| Tammi L. Gaskins Chief Commercial Officer | Nov 17, 2025 | Sale | −6,016 | $3.32 | $19.97K | 235,264 |
| Alexander J. Denner Director, 10% owner | Sep 15, 2025 | Award | +11,718 | – | – | 247,680 |
| Minardo John Chief Legal Officer | Aug 11, 2025 | Sale | −7,754 | $0.84 | $6.51K | 400,378 |
| Ronald Silver Principal Accounting Officer | Aug 11, 2025 | Sale | −2,846 | $0.84 | $2.39K | 276,809 |
| Tammi L. Gaskins Chief Commercial Officer | Aug 11, 2025 | Sale | −1,316 | $0.84 | $1.11K | 241,280 |
| Gregory S. Martini Chief Financial Officer | Aug 11, 2025 | Sale | −1,265 | $0.84 | $1.06K | 182,545 |
| Capital Management LP Sarissa 10% owner | Jun 13, 2025 | Award | +24,193 | – | – | 235,962 |
| Julie McHugh Director | Jun 10, 2025 | Award | +45,000 | – | – | 208,839 |
| Catherine Moukheibir Director | Jun 10, 2025 | Award | +45,000 | – | – | 117,944 |
| Mark G. Currie Director | Jun 10, 2025 | Award | +45,000 | – | – | 613,419 |
| Andrew Dreyfus Director | Jun 10, 2025 | Award | +45,000 | – | – | 228,313 |
| Alexander J. Denner Director, 10% owner | Jun 10, 2025 | Award | +45,000 | – | – | 211,769 |
| Jon R. Duane Director | Jun 10, 2025 | Award | +45,000 | – | – | 190,339 |
| Jay Shepard Director | Jun 10, 2025 | Award | +45,000 | – | – | 171,555 |
| Marla L. Kessler Director | Jun 10, 2025 | Award | +45,000 | – | – | 165,883 |
| Thomas A. MCCOURT Chief Executive Officer, Director | May 20, 2025 | Award | +540,000 | – | – | 1,687,281 |
| Tammi L. Gaskins Chief Commercial Officer | May 16, 2025 | Sale | −2,563 | $0.58 | $1.49K | 242,596 |
| Thomas A. MCCOURT Chief Executive Officer, Director | May 16, 2025 | Sale | −13,353 | $0.58 | $7.74K | 1,147,281 |
| Capital Management LP Sarissa 10% owner | Apr 2, 2025 | Award | +10,416 | – | – | 166,769 |
| Ronald Silver Principal Accounting Officer | Feb 10, 2025 | Sale | −12,048 | $1.76 | $21.20K | 279,655 |
| Minardo John Chief Legal Officer | Feb 10, 2025 | Award | +122,222 | – | – | 447,070 |
| Minardo John Chief Legal Officer | Feb 10, 2025 | Sale | −38,938 | $1.76 | $68.53K | 408,132 |
| Gregory S. Martini Chief Financial Officer | Feb 10, 2025 | Sale | −12,052 | $1.76 | $21.21K | 183,810 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Feb 10, 2025 | Sale | −41,269 | $1.76 | $72.63K | 554,007 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ironwood Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 169,040 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael Shetzline Former Officer | Sep 23, 2026 | 83,306 | $377.38K | Sep 24, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan |
| Ronald Silver Officer | Jul 7, 2026 | 127,890 | $560.16K | Jul 7, 2026 | Restricted Stock Units |
| Julie McHugh Director | Jun 16, 2026 | 21,571 | $79.60K | Jun 16, 2026 | Restricted Stock Units |
| Gregory S. Martini Officer | Feb 20, 2026 | 20,163 | $92.95K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Tammi L. Gaskins Officer | Feb 20, 2026 | 19,775 | $91.16K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Thomas A. MCCOURT Officer, Director | Feb 20, 2026 | 182,185 | $839.87K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Minardo John Officer | Feb 20, 2026 | 33,528 | $154.56K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Michael Shetzline Officer | Feb 20, 2026 | 29,937 | $138.01K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Ronald Silver Officer | Jan 5, 2026 | 35,416 | $151.23K | Jan 5, 2026 | Employee Stock Purchase Plan |
| Tammi L. Gaskins Officer | Nov 14, 2025 | 6,324 | $21.31K | Nov 17, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements |
| Minardo John Officer | Aug 8, 2025 | 8,281 | $7.29K | Aug 11, 2025 | Restricted Stock Unit award granted pursuant to Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Tammi L. Gaskins Officer | Aug 8, 2025 | 1,406 | $1.24K | Aug 11, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements |
| Gregory S. Martini Officer | Aug 8, 2025 | 1,351 | $1.19K | Aug 11, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements |
| Thomas A. MCCOURT Officer, Director | May 16, 2025 | 14,661 | $8.65K | May 19, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Tammi L. Gaskins Officer | May 16, 2025 | 2,814 | $1.66K | May 19, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
See a number that looks wrong?